Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 11, 2013

Primary Completion Date

May 26, 2016

Study Completion Date

January 16, 2017

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Ventavis (Iloprost, BAYQ6256)

Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.

Trial Locations (1)

Multiple Locations